Sandu Pharmaceuticals Limited

BSE:524703 Stock Report

Market Cap: ₹524.2m

Sandu Pharmaceuticals Management

Management criteria checks 2/4

Sandu Pharmaceuticals' CEO is Umesh Sandu, appointed in Jun 2018, has a tenure of 6.67 years. total yearly compensation is ₹8.45M, comprised of 94.3% salary and 5.7% bonuses, including company stock and options. directly owns 14.37% of the company’s shares, worth ₹75.35M. The average tenure of the management team and the board of directors is 6.7 years and 1.5 years respectively.

Key information

Umesh Sandu

Chief executive officer

₹8.4m

Total compensation

CEO salary percentage94.3%
CEO tenure6.7yrs
CEO ownership14.4%
Management average tenure6.7yrs
Board average tenure1.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Umesh Sandu's remuneration changed compared to Sandu Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

₹15m

Jun 30 2024n/an/a

₹15m

Mar 31 2024₹8m₹8m

₹15m

Dec 31 2023n/an/a

₹11m

Sep 30 2023n/an/a

₹14m

Jun 30 2023n/an/a

₹12m

Mar 31 2023₹9m₹8m

₹15m

Dec 31 2022n/an/a

₹15m

Sep 30 2022n/an/a

₹15m

Jun 30 2022n/an/a

₹16m

Mar 31 2022₹7m₹7m

₹16m

Dec 31 2021n/an/a

₹17m

Sep 30 2021n/an/a

₹15m

Jun 30 2021n/an/a

₹15m

Mar 31 2021₹4m₹3m

₹11m

Dec 31 2020n/an/a

₹7m

Sep 30 2020n/an/a

₹6m

Jun 30 2020n/an/a

₹4m

Mar 31 2020₹4m₹3m

₹7m

Dec 31 2019n/an/a

₹7m

Sep 30 2019n/an/a

₹6m

Jun 30 2019n/an/a

₹7m

Mar 31 2019₹4m₹3m

₹7m

Dec 31 2018n/an/a

₹9m

Sep 30 2018n/an/a

₹14m

Jun 30 2018n/an/a

₹14m

Mar 31 2018₹3m₹3m

₹6m

Compensation vs Market: Umesh's total compensation ($USD97.48K) is above average for companies of similar size in the Indian market ($USD41.54K).

Compensation vs Earnings: Umesh's compensation has been consistent with company performance over the past year.

CEO

Umesh Sandu (57 yo)

6.7yrs

Tenure

₹8,448,000

Compensation

Mr. Umesh Bhaskar Sandu serves as the Managing Director and Executive Director of Sandu Pharmaceuticals Limited since June 2, 2018 and served as its Company Secretary.

Leadership Team

NamePositionTenureCompensationOwnership
Umesh Sandu
MD & Executive Director6.7yrs₹8.45m14.37%
₹ 75.4m
Vijay Kajarekar
Chief Financial Officerless than a year₹894.29kno data
Pratika Mhambray
Compliance Officer & Company Secretary9.8yrs₹848.00kno data

6.7yrs

Average Tenure

Experienced Management: 524703's management team is seasoned and experienced (6.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Umesh Sandu
MD & Executive Director6.7yrs₹8.45m14.37%
₹ 75.4m
Shashank Sandu
Non-Executive Director13.7yrsno data14.17%
₹ 74.3m
Jayshree Sandu
Non-Executive Non-Independent Women Directorless than a yearno data7.63%
₹ 40.0m
Shubhada Sandu
Non-Executive Director9.8yrsno data0.10%
₹ 542.6k
Ajit Kantak
Non-Executive Independent Director1.5yrsno datano data
Balaram Vishwanathan
Non Executive Independent Chairman1.5yrsno datano data
Vijay Kottapall
Non-Executive Independent Directorless than a yearno datano data
Vinay Kottapalli
Non Executive Independent Directorno datano datano data

1.5yrs

Average Tenure

60yo

Average Age

Experienced Board: 524703's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 05:37
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sandu Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution